HealthFlex
×
  • About Us
    • Company Management
    • Meet Our Team
    • Board of Directors
    • Scientific Advisory Board
    • Clinical Advisory Board
    • Careers
  • Technologies
    • Oncoprex® Delivery System
    • Reqorsa® Gene Therapy
    • GPX-002
  • Programs
    • Oncology
    • Diabetes
  • Clinical Trials
    • Pipeline
    • ONC-001
    • ONC-002
    • Acclaim-1
    • Acclaim-3
    • DIA-001 and DIA-002
    • Expanded Access Policy
  • Investors
    • Company Profile
    • Stock Information
    • SEC Filings
    • Analyst Coverage
    • Corporate Governance
    • Shareholder FAQ
    • Downloads
    • Events
  • News
    • Press Releases
    • Blog Posts
    • Media Coverage
    • Videos
  • Contact
Celina Laney

Celina Laney

Chief of Staff

Celina Laney joined Genprex in June of 2018, and she serves as the company’s Chief of Staff. In this role, Celina is responsible for overseeing Genprex’s effectiveness by streamlining administrative procedures and organizing office operations while also coordinating with all company departments, including HR, finance and IT, as well as outside vendors and service providers, to ensure office operations and procedures are controlled and working efficiently. Prior to officially joining the Genprex team, Celina served as an executive assistant to Genprex’s Chief Executive Officer since 2010. She has more than 18 years of experience serving in various legal secretary and litigation assistant roles for several law firms across Austin and Houston. In these roles she held many responsibilities including conducting research, preparing documents for court hearings, scheduling meetings, and providing case status updates to clients, which helped play a crucial role in the firms’ successes.

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes.

(877) 774-GNPX (4679)

3300 Bee Cave Road, Suite 650-227 Austin, TX 78746

Quick Links

  • About Us
  • Clinical Trials
  • Investors
  • Downloads
  • Press Releases
  • X
  • Facebook
  • LinkedIn

Latest News

  • Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes May 7
  • Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma May 6
  • Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting Apr 30
  • Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting Apr 29
Designed and Secured by Barsec
Copyright ©2025 all rights reserved.
Home - Privacy Policy - Terms of Use